k141_41819_4	SARG|gb|CDO61516.1|ARO:3003949|efrB	28.9	152	547	362	7.82e-10	59.7
k141_41819_4	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	28.9	173	547	293	1.26e-08	55.5
k141_41819_4	SARG|gb|AEO25219.1|ARO:3004651|lin	27.5	182	547	523	4.42e-08	54.7
k141_41819_4	SARG|gi|488321355|ref|WP_002390740.1|	29.8	168	547	492	1.71e-07	52.8
k141_41819_4	SARG|gi|488231473|ref|WP_002302681.1|	30.6	170	547	492	2.25e-07	52.4
k141_41819_4	SARG|gi|488216250|ref|WP_002287458.1|	30.6	170	547	492	2.25e-07	52.4
k141_41819_4	SARG|gi|488247627|ref|WP_002318835.1|	30.6	170	547	492	2.25e-07	52.4
k141_41819_4	SARG|AY004350.gene.p01	30.6	170	547	492	2.25e-07	52.4
k141_41819_4	SARG|gi|171851258|emb|CAQ04234.1|	44.1	59	547	483	6.78e-07	50.8
k141_29885_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	38.3	107	102	255	3.15e-19	78.2
k141_47890_4	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.2	202	227	204	9.54e-17	74.7
k141_53950_1	SARG|gb|BAE06008.1|ARO:3003699|mexQ	26.1	976	964	1053	1.00e-44	174
k141_53950_1	SARG|YP_002800512	24.7	956	964	1057	2.20e-43	170
k141_53950_1	SARG|gi|489544697|ref|WP_003449357.1|	24.1	950	964	1060	2.21e-43	170
k141_53950_1	SARG|gi|655279967|ref|WP_028689378.1|	23.9	974	964	1059	6.76e-43	168
k141_53950_1	SARG|gi|512735233|ref|WP_016493075.1|	24.3	952	964	1062	6.80e-43	168
k141_53950_1	SARG|YP_001749316	24.0	966	964	1059	1.18e-42	167
k141_53950_1	SARG|gi|764528042|ref|WP_044407471.1|	24.0	964	964	1062	1.19e-42	167
k141_53950_1	SARG|gi|512743205|ref|WP_016499908.1|	24.0	965	964	1059	2.07e-42	167
k141_53950_1	SARG|NP_745564	24.0	965	964	1059	2.07e-42	167
k141_53950_1	SARG|YP_001668745	24.0	965	964	1059	2.07e-42	167
k141_36100_2	SARG|gi|702897513|ref|WP_033300957.1|	27.9	197	277	601	2.00e-13	68.9
k141_36100_2	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	29.0	193	277	343	3.02e-13	67.8
k141_36100_2	SARG|gi|664170108|ref|WP_030704355.1|	30.4	184	277	603	8.81e-13	67.0
k141_36100_2	SARG|gi|501350226|ref|WP_012381861.1|	30.4	184	277	603	8.81e-13	67.0
k141_36100_2	SARG|gi|490068471|ref|WP_003970646.1|	30.4	184	277	603	8.81e-13	67.0
k141_36100_2	SARG|gi|664085850|ref|WP_030624018.1|	29.9	184	277	605	1.19e-12	66.6
k141_36100_2	SARG|gi|664100597|ref|WP_030638327.1|	27.4	197	277	601	1.59e-12	66.2
k141_36100_2	SARG|gi|505389066|ref|WP_015576168.1|	27.4	197	277	601	1.59e-12	66.2
k141_36100_2	SARG|gi|503923650|ref|WP_014157644.1|	27.4	197	277	601	1.59e-12	66.2
k141_36100_2	SARG|gi|664352659|ref|WP_030880307.1|	27.4	197	277	601	2.13e-12	65.9
k141_71812_1	SARG|ZP_04638974	47.1	384	413	563	2.40e-92	288
k141_71812_1	SARG|gi|740410309|ref|WP_038243756.1|	46.6	384	413	563	3.39e-92	287
k141_71812_1	SARG|YP_001401994	46.6	384	413	563	4.77e-92	287
k141_71812_1	SARG|AAS61092	46.6	384	413	563	6.72e-92	286
k141_71812_1	SARG|YP_001007250	47.1	384	413	563	9.46e-92	286
k141_71812_1	SARG|gi|896190680|ref|WP_049199932.1|	46.1	384	413	563	1.46e-90	283
k141_71812_1	SARG|YP_001605795	46.9	384	413	562	5.61e-90	281
k141_71812_1	SARG|ZP_04631861	47.4	369	413	543	1.90e-89	280
k141_71812_1	SARG|ZP_04635128	47.2	369	413	543	5.31e-89	278
k141_71812_1	SARG|gi|1001786599|ref|WP_061324791.1|	45.1	381	413	563	6.31e-89	279
k141_71812_6	SARG|gi|505807117|ref|WP_015704872.1|	29.4	299	532	648	2.71e-25	108
k141_71812_6	SARG|gi|695793471|ref|WP_032707680.1|	29.8	299	532	648	4.82e-25	108
k141_71812_6	SARG|gi|976146774|ref|WP_059305359.1|	29.4	299	532	648	4.82e-25	108
k141_71812_6	SARG|gi|1022664304|ref|WP_063420886.1|	29.4	299	532	648	4.82e-25	108
k141_71812_6	SARG|gi|695797094|ref|WP_032711285.1|	29.4	299	532	648	4.82e-25	108
k141_71812_6	SARG|gi|823299155|ref|WP_047054544.1|	29.4	299	532	648	4.82e-25	108
k141_71812_6	SARG|gi|823326845|ref|WP_047080664.1|	29.4	299	532	648	6.43e-25	107
k141_71812_6	SARG|gi|823302270|ref|WP_047057473.1|	29.4	299	532	648	6.43e-25	107
k141_71812_6	SARG|gi|1022688710|ref|WP_063443532.1|	29.4	299	532	648	8.58e-25	107
k141_71812_6	SARG|gi|823309640|ref|WP_047064288.1|	29.4	299	532	648	8.58e-25	107
k141_71812_9	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.4	188	326	255	6.38e-29	110
k141_36236_3	NCBI|EAC4468893.1|1|1|emrC_Lis|emrC_Lis||1|QUATERNARY_AMMONIUM|QUATERNARY_AMMONIUM|multidrug_efflux_transporter_outer_membrane_subunit_EmrC|AMR|quaternary	35.6	101	105	128	5.70e-14	62.0
k141_36236_3	SARG|NC_010410.6003348.p01	33.7	101	105	109	1.65e-12	57.8
k141_36236_3	SARG|gi|489421661|ref|WP_003327389.1|	40.7	86	105	105	1.20e-11	55.5
k141_36236_3	SARG|gb|AEH26330.1|ARO:3005009|qacE	33.0	106	105	110	3.75e-11	54.3
k141_36236_3	SARG|gb|AAC44316.1|ARO:3005010|qacEdelta1	34.0	97	105	115	6.47e-10	51.2
k141_36236_3	SARG|gi|291483835|dbj|BAI84910.1|	35.3	85	105	105	2.27e-08	47.0
k141_36236_3	CARD|gb|BAH63251.1|ARO:3004580|Kpne_KpnE	36.5	104	105	120	3.02e-08	47.0
k141_36236_3	SARG|gi|489311091|ref|WP_003218500.1|	35.3	85	105	105	3.20e-08	46.6
k141_36236_3	SARG|gi|320021335|gb|ADV96321.1|	35.3	85	105	105	3.20e-08	46.6
k141_36236_3	SARG|gi|1044625135|gb|OCB99622.1|	30.7	101	105	163	7.98e-08	46.6
k141_66012_1	SARG|gb|BAD89844.2|ARO:3000753|abeM	31.8	400	476	448	8.74e-52	180
k141_66012_1	SARG|gb|AAG04750.1|ARO:3004077|PmpM	30.5	459	476	477	1.15e-50	178
k141_66012_1	SARG|gi|1004039946|ref|WP_061495278.1|	29.1	399	476	457	5.33e-44	159
k141_362_3	CARD|gb|AAK37618.1|ARO:3005008|TxR	41.5	246	602	318	2.95e-54	186
k141_362_3	SARG|ZP_02848503	29.8	121	602	221	7.75e-08	52.4
k141_362_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	121	602	219	2.49e-07	50.8
k141_362_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	121	602	219	2.49e-07	50.8
k141_362_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	121	602	220	2.51e-07	50.8
k141_362_3	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.2	121	602	220	3.38e-07	50.4
k141_362_3	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.0	71	602	220	1.49e-06	48.5
k141_36552_3	SARG|M57437.gene.p01	29.8	242	289	548	3.36e-16	77.4
k141_36552_3	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	25.9	216	289	487	1.69e-12	66.2
k141_36552_3	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	25.9	216	289	487	1.69e-12	66.2
k141_570_2	SARG|AUI09862.1	43.2	271	290	287	1.16e-48	162
k141_570_2	SARG|gi|728806562|ref|WP_033917658.1|	38.9	270	290	271	1.21e-43	149
k141_570_2	SARG|gi|499192666|ref|WP_010890206.1|	38.9	270	290	271	2.40e-43	148
k141_570_2	SARG|gi|446966006|ref|WP_001043262.1|	38.9	270	290	271	2.40e-43	148
k141_570_2	SARG|gi|695268609|ref|WP_032490786.1|	38.6	272	290	272	3.46e-43	147
k141_570_2	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	38.5	270	290	271	9.39e-43	146
k141_570_2	SARG|gi|638947703|ref|WP_024439711.1|	38.5	270	290	271	9.39e-43	146
k141_570_2	SARG|gi|916164813|ref|WP_050960181.1|	38.5	270	290	271	9.39e-43	146
k141_570_2	SARG|gb|AAL59753.1|ARO:3000412|sul2	38.5	270	290	271	1.32e-42	146
k141_570_2	SARG|gi|550552396|ref|WP_022631488.1|	38.5	270	290	271	1.32e-42	146
k141_24797_4	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.7	101	220	231	1.59e-07	49.3
k141_930_3	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.0	222	245	343	6.63e-32	118
k141_930_3	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	29.3	215	245	528	2.18e-12	65.1
k141_24935_1	SARG|gi|542061059|gb|ERI11611.1|	26.8	231	309	316	4.30e-21	90.5
k141_24935_1	SARG|YP_001373621	25.6	227	309	318	5.46e-17	79.0
k141_24935_1	SARG|U82085.gene.p01	35.6	59	309	552	7.56e-06	46.2
k141_72702_5	megares|MEG_1246|Drugs|beta-lactam|Class_A_betalactamases|BLAA_1	31.7	325	377	339	3.55e-56	186
k141_42950_3	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	30.0	100	218	231	1.33e-08	52.4
k141_42950_3	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	29.0	100	218	231	6.20e-08	50.4
k141_42950_3	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	28.0	100	218	231	1.55e-07	49.3
k141_42950_3	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	28.0	100	218	231	1.55e-07	49.3
k141_42950_3	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	28.3	99	218	231	2.86e-07	48.5
k141_73061_10	NCBI|WP_446913730.1|1|1|estX|estX||2|TYLOSIN|MACROLIDE|macrolide_esterase_EstX|AMR|macrolide	27.5	265	298	280	2.18e-22	93.2
k141_73061_10	NCBI|WP_016242844.1|1|1|estX|estX||2|TYLOSIN|MACROLIDE|macrolide_esterase_EstX|AMR|macrolide	27.5	265	298	280	3.02e-22	92.8
k141_73061_10	NCBI|WP_080153612.1|1|1|estX|estX||2|TYLOSIN|MACROLIDE|macrolide_esterase_EstX|AMR|macrolide	27.5	265	298	279	4.11e-22	92.4
k141_73061_10	NCBI|WP_001456218.1|1|1|estX-3|estX||2|TYLOSIN|MACROLIDE|macrolide_esterase_EstX-3|AMR|macrolide	27.5	265	298	280	4.18e-22	92.4
k141_73061_10	NCBI|WP_446913731.1|1|1|estX|estX||2|TYLOSIN|MACROLIDE|macrolide_esterase_EstX|AMR|macrolide	27.5	265	298	280	4.18e-22	92.4
k141_73061_10	NCBI|WP_047660123.1|1|1|estX|estX||2|TYLOSIN|MACROLIDE|macrolide_esterase_EstX|AMR|macrolide	27.5	265	298	280	4.18e-22	92.4
k141_73061_10	megares|MEG_5255|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	27.5	265	298	308	6.41e-22	92.4
k141_73061_10	NCBI|WP_446913729.1|1|1|estX|estX||2|TYLOSIN|MACROLIDE|macrolide_esterase_EstX|AMR|macrolide	27.5	265	298	280	1.10e-21	91.3
k141_73061_10	NCBI|WP_446913733.1|1|2|estX|estX||2|TYLOSIN|MACROLIDE|bifunctional_putative_esterase_EstX/streptothricin_N-acetyltransferase_Sat1|AMR|multidrug	27.5	265	298	485	2.06e-21	92.8
k141_73061_10	megares|MEG_6159|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	27.5	265	298	501	2.17e-21	92.8
k141_73061_11	SARG|YP_002850217	31.2	295	320	660	1.15e-25	106
k141_73061_11	SARG|gi|692997842|ref|WP_032184680.1|	29.9	324	320	660	2.11e-25	105
k141_73061_11	SARG|gi|486404556|ref|WP_001607766.1|	30.2	325	320	660	2.85e-25	105
k141_73061_11	SARG|gi|693074684|ref|WP_032237896.1|	29.9	324	320	660	3.86e-25	104
k141_73061_11	SARG|gi|851965596|ref|WP_048234849.1|	30.8	295	320	660	5.21e-25	104
k141_73061_11	SARG|gi|583082565|ref|WP_024155124.1|	29.3	294	320	660	5.21e-25	104
k141_73061_11	SARG|gi|487138644|ref|WP_001630041.1|	29.3	294	320	660	5.21e-25	104
k141_73061_11	SARG|gi|446571422|ref|WP_000648768.1|	28.9	294	320	660	5.21e-25	104
k141_73061_11	SARG|gi|920043689|ref|WP_052939451.1|	29.3	294	320	660	7.05e-25	103
k141_73061_11	SARG|gi|1002387632|ref|WP_061375456.1|	29.3	294	320	660	7.05e-25	103
k141_18851_4	CARD|gb|ADM92605.1|ARO:3000553|adeR	26.7	221	209	247	9.07e-11	58.5
k141_18851_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	28.2	110	209	229	1.30e-09	55.1
k141_25096_5	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	34.1	123	120	712	2.91e-19	80.9
k141_43005_3	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	31.9	113	232	252	1.54e-07	49.7
k141_91050_3	SARG|gi|737310392|ref|WP_035293250.1|	27.2	254	326	323	6.75e-22	93.2
k141_91050_3	SARG|DQ018711.1.gene4.p01	27.6	254	326	322	2.37e-21	91.7
k141_91050_3	SARG|gi|738848198|ref|WP_036737307.1|	27.6	254	326	323	3.29e-21	91.3
k141_91050_3	SARG|FJ349556.1.gene5.p01	27.8	252	326	326	3.42e-21	91.3
k141_91050_3	SARG|gi|749574782|ref|WP_040203616.1|	27.5	247	326	323	4.11e-20	88.2
k141_91050_3	SARG|AF155139.2.gene6.p01	28.0	254	326	322	7.60e-20	87.4
k141_91050_3	SARG|gi|552942232|ref|WP_023043160.1|	28.2	255	326	323	1.05e-19	87.0
k141_91050_3	SARG|AAY52004	27.1	247	326	322	1.42e-19	86.7
k141_91050_3	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	27.9	247	326	314	6.20e-19	84.7
k141_91050_3	SARG|AY082011.1.gene6.p01	27.8	255	326	323	6.87e-19	84.7
k141_49278_2	SARG|gi|696368937|ref|WP_032943949.1|	44.6	222	238	648	2.16e-57	191
k141_49278_2	SARG|gi|851913025|ref|WP_048215946.1|	44.6	222	238	648	2.16e-57	191
k141_49278_2	SARG|YP_002850060	44.6	222	238	648	2.16e-57	191
k141_49278_2	SARG|gi|489930965|ref|WP_003834285.1|	44.6	222	238	648	2.16e-57	191
k141_49278_2	SARG|gi|491270241|ref|WP_005128370.1|	44.6	222	238	648	3.01e-57	191
k141_49278_2	SARG|gi|851922185|ref|WP_048218206.1|	44.6	222	238	648	3.01e-57	191
k141_49278_2	SARG|gi|949718947|ref|WP_057063453.1|	44.6	222	238	648	3.01e-57	191
k141_49278_2	SARG|gi|696375069|ref|WP_032949617.1|	44.6	222	238	648	3.01e-57	191
k141_49278_2	SARG|gi|696361545|ref|WP_032936694.1|	44.6	222	238	648	3.01e-57	191
k141_49278_2	SARG|gi|489936909|ref|WP_003840216.1|	44.6	222	238	648	3.01e-57	191
k141_84917_2	SARG|gb|AAK76137.1|ARO:3000024|patA	28.2	202	260	564	3.89e-12	64.7
k141_84917_2	SARG|gi|655401130|ref|WP_028800283.1|	29.7	202	260	599	1.87e-10	59.7
k141_84917_2	SARG|gi|930482089|ref|WP_054228897.1|	30.2	202	260	599	3.37e-10	58.9
k141_84917_2	SARG|gi|985844137|ref|WP_060895163.1|	30.2	202	260	599	3.37e-10	58.9
k141_84917_2	SARG|gi|860594225|ref|WP_048475168.1|	29.7	202	260	620	1.11e-09	57.4
k141_84917_2	SARG|gi|953808775|ref|WP_058042812.1|	27.4	230	260	608	1.47e-09	57.0
k141_84917_2	SARG|gi|664244930|ref|WP_030776974.1|	29.7	202	260	601	3.54e-09	55.8
k141_84917_2	SARG|gi|943909899|ref|WP_055545300.1|	28.7	202	260	601	3.54e-09	55.8
k141_84917_2	SARG|gi|648667297|ref|WP_026359044.1|	29.6	213	260	605	3.55e-09	55.8
k141_84917_2	SARG|gi|928900436|ref|WP_053931243.1|	28.4	204	260	600	4.75e-09	55.5
k141_55238_3	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	24.4	234	260	568	3.47e-09	55.8
k141_55238_3	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.2	224	260	552	4.60e-09	55.5
k141_55238_3	SARG|GQ205627.2.gene1.p01	21.0	224	260	525	1.09e-08	54.3
k141_55238_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	210	260	655	1.18e-08	54.3
k141_55238_3	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	210	260	655	1.18e-08	54.3
k141_55238_3	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	210	260	655	1.18e-08	54.3
k141_55238_3	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	210	260	655	1.18e-08	54.3
k141_55238_3	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	210	260	655	1.18e-08	54.3
k141_55238_3	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	210	260	655	1.18e-08	54.3
k141_55238_3	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.6	210	260	655	1.18e-08	54.3
k141_67630_1	SARG|gb|BAE06006.1|ARO:3003705|mexN	23.7	342	386	1036	1.36e-22	99.0
k141_67630_1	SARG|ZP_02909221	22.1	348	386	1045	6.77e-18	84.7
k141_67630_1	SARG|YP_001119417	21.4	346	386	1045	2.16e-17	83.2
k141_67630_1	SARG|ZP_02892568	21.8	348	386	1045	2.16e-17	83.2
k141_67630_1	SARG|YP_773413	21.9	347	386	1045	3.85e-17	82.4
k141_67630_1	SARG|YP_001808247	22.3	310	386	1045	1.63e-16	80.5
k141_67630_1	SARG|gb|BAE06008.1|ARO:3003699|mexQ	24.1	315	386	1053	1.64e-16	80.5
k141_67630_1	SARG|YP_001764894	21.7	309	386	1046	2.18e-16	80.1
k141_67630_1	SARG|YP_369007	21.0	347	386	1045	9.20e-16	78.2
k141_67630_1	SARG|CAR51973	21.7	309	386	1046	9.20e-16	78.2
k141_1905_1	SARG|gb|AAG04750.1|ARO:3004077|PmpM	30.6	350	349	477	9.05e-34	129
k141_19580_2	SARG|gi|542061059|gb|ERI11611.1|	36.0	197	367	316	4.85e-36	132
k141_19580_2	SARG|gi|500194536|ref|WP_011867743.1|	36.5	197	367	306	5.63e-34	126
k141_19580_2	SARG|ABB80128	35.5	200	367	306	7.84e-34	126
k141_19580_2	SARG|gi|445996719|ref|WP_000074574.1|	35.5	197	367	309	8.35e-34	126
k141_19580_2	SARG|gi|445996710|ref|WP_000074565.1|	35.0	197	367	309	1.16e-33	125
k141_19580_2	SARG|P42332	35.5	197	367	306	1.52e-33	125
k141_19580_2	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	35.5	197	367	306	1.52e-33	125
k141_19580_2	SARG|gi|445996709|ref|WP_000074564.1|	35.0	197	367	309	1.62e-33	125
k141_19580_2	SARG|gi|445996729|ref|WP_000074584.1|	35.5	197	367	309	1.62e-33	125
k141_19580_2	SARG|gi|507055561|ref|WP_016126482.1|	36.0	197	367	309	1.62e-33	125
k141_19599_1	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	47.1	221	214	252	1.37e-61	191
k141_19599_1	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	44.7	208	214	225	4.32e-54	171
k141_19599_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.0	205	214	228	3.22e-43	144
k141_19599_1	CARD|gb|AAG05188.1|ARO:3005068|ParR	37.5	208	214	235	6.89e-41	138
k141_19599_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	40.4	208	214	229	5.17e-39	133
k141_19599_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.6	189	214	232	1.74e-37	129
k141_19599_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.6	189	214	232	1.74e-37	129
k141_19599_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.2	211	214	232	2.72e-36	126
k141_19599_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.6	211	214	247	5.59e-36	125
k141_19599_1	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.7	215	214	235	2.30e-35	124
k141_38184_1	SARG|gi|2708772|gb|AAB96371.1|	27.9	290	329	391	5.48e-16	77.0
k141_38184_1	SARG|NP_044444	27.9	290	329	391	5.48e-16	77.0
k141_38184_1	SARG|AF024666.2.gene33.p01	27.9	290	329	391	5.48e-16	77.0
k141_38184_1	SARG|YP_251195	27.9	290	329	391	9.97e-16	76.3
k141_38184_1	megares|MEG_1780|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	27.0	274	329	391	4.43e-15	74.3
k141_38184_1	SARG|AF015087.1.gene1.p01	27.0	274	329	391	4.43e-15	74.3
k141_38184_1	SARG|gb|CAA78046.1|ARO:3002701|Rfas_cmr	24.5	294	329	391	2.19e-12	66.2
k141_38184_1	megares|MEG_1781|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	24.5	294	329	391	2.19e-12	66.2
k141_38235_5	SARG|gb|APB03219.1|ARO:3003986|TaeA	28.2	248	220	648	3.30e-22	93.2
k141_38235_5	ResF|poxtA-Ef_1_WP094899500.1_1	21.5	214	220	538	1.49e-08	53.1
k141_38235_5	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	21.5	214	220	543	1.50e-08	53.1
k141_38235_5	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	21.5	214	220	543	1.50e-08	53.1
k141_38235_5	SARG|gi|736993687|ref|WP_034989673.1|	34.5	87	220	513	5.18e-07	48.5
k141_38235_5	SARG|AF024666.2.gene6.p01	34.5	87	220	513	5.18e-07	48.5
k141_38235_5	SARG|gi|171851258|emb|CAQ04234.1|	33.3	87	220	483	6.82e-07	48.1
k141_14615_2	ResF|mre(A)_1_U92073_1	31.0	287	318	310	3.08e-40	142
k141_14615_2	SARG|gb|AAB64408.1|ARO:3007050|mreA	31.0	287	318	311	3.15e-40	142
k141_14615_3	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	31.8	176	209	1024	1.25e-25	102
k141_14615_3	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.8	176	209	1024	1.25e-25	102
k141_14615_3	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.8	176	209	1024	1.25e-25	102
k141_14615_3	SARG|gb|CAA53189|ARO:3000521|mupA	31.8	176	209	1024	1.25e-25	102
k141_14615_3	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	30.1	176	209	1033	4.29e-25	101
k141_14615_3	SARG|gb|AEY83581|ARO:3000510|mupB	30.1	176	209	1033	4.29e-25	101
k141_7770_3	SARG|gi|823291602|ref|WP_047047573.1|	32.8	204	259	648	6.87e-19	84.7
k141_7770_3	SARG|gi|823326845|ref|WP_047080664.1|	32.4	204	259	648	1.70e-18	83.6
k141_7770_3	SARG|gi|695793471|ref|WP_032707680.1|	32.4	204	259	648	1.70e-18	83.6
k141_7770_3	SARG|gi|823302270|ref|WP_047057473.1|	32.4	204	259	648	1.70e-18	83.6
k141_7770_3	SARG|gi|976146774|ref|WP_059305359.1|	32.4	204	259	648	1.70e-18	83.6
k141_7770_3	SARG|gi|1022664304|ref|WP_063420886.1|	32.4	204	259	648	1.70e-18	83.6
k141_7770_3	SARG|gi|823309640|ref|WP_047064288.1|	32.4	204	259	648	1.70e-18	83.6
k141_7770_3	SARG|gi|505807117|ref|WP_015704872.1|	32.4	204	259	648	1.70e-18	83.6
k141_7770_3	SARG|gi|518923394|ref|WP_020079269.1|	32.4	204	259	648	1.70e-18	83.6
k141_7770_3	SARG|gi|695797094|ref|WP_032711285.1|	32.4	204	259	648	1.70e-18	83.6
k141_7786_3	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	535	647	655	9.56e-90	291
k141_7786_3	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	535	647	655	1.34e-89	291
k141_7786_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	535	647	655	1.40e-88	288
k141_7786_3	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	535	647	655	1.40e-88	288
k141_7786_3	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	535	647	655	1.40e-88	288
k141_7786_3	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	535	647	655	1.40e-88	288
k141_7786_3	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	535	647	655	1.40e-88	288
k141_7786_3	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	535	647	655	1.96e-88	288
k141_7786_3	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	535	647	655	2.74e-88	287
k141_7786_3	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	535	647	655	2.74e-88	287
k141_19926_2	megares|MEG_7256|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|TLRC_1	31.9	188	571	540	3.96e-09	58.2
k141_19926_2	SARG|gb|WP_082039181.1|ARO:3007028|salD	27.4	208	571	544	1.11e-07	53.5
k141_19926_2	SARG|gi|694064328|ref|WP_032410816.1|	28.1	199	571	646	1.11e-06	50.4
k141_19926_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.6	152	571	362	1.32e-06	49.7
k141_19926_2	SARG|gi|171851258|emb|CAQ04234.1|	35.1	77	571	483	5.06e-06	48.1
k141_19926_2	SARG|gi|736993687|ref|WP_034989673.1|	29.6	98	571	513	6.90e-06	47.8
k141_19926_2	SARG|AF024666.2.gene6.p01	29.6	98	571	513	6.90e-06	47.8
k141_68331_1	NCBI|WP_434062363.1|1|1|dfrA53|dfrA53|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA53|AMR|diaminopyrimidine	41.7	144	170	166	3.54e-33	114
k141_68331_1	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	42.6	136	170	170	1.58e-32	113
k141_68331_1	SARG|gb|AAA25550.1|ARO:3003105|dfrA3	46.6	133	170	162	3.58e-32	112
k141_68331_1	SARG|gb|ABO40886.1|ARO:3004645|dfrI	40.6	133	170	191	3.91e-32	112
k141_68331_1	NCBI|WP_012779617.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	33.1	166	170	163	1.47e-31	110
k141_68331_1	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	41.0	134	170	164	8.53e-31	108
k141_68331_1	SARG|gb|BAE15963.1|ARO:3002868|dfrG	31.9	166	170	165	6.98e-30	106
k141_68331_1	SARG|gb|CBL80435.1|ARO:3002869|dfrK	31.3	166	170	163	1.32e-29	105
k141_68331_1	NCBI|WP_031775848.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	31.3	166	170	163	1.32e-29	105
k141_68331_1	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	38.6	140	170	164	3.82e-29	104
k141_38438_2	SARG|gi|1028100561|ref|WP_063856696.1|	35.0	254	320	349	2.45e-34	127
k141_38438_2	SARG|KF478993.1.gene3.p01	32.3	347	320	346	2.35e-33	124
k141_38438_2	SARG|gi|752682279|ref|WP_041330231.1|	34.3	254	320	349	6.68e-33	123
k141_38438_2	SARG|JF802084.2.gene1.p01	27.7	347	320	343	4.34e-31	118
k141_38438_2	SARG|gi|777763073|gb|AJY53584.1|	27.7	347	320	343	6.03e-31	118
k141_38438_2	NCBI|WP_011029110.1|1|1|vanA-Sc|vanA-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanA-Sc|AMR|glycopeptide	35.0	286	320	346	3.28e-30	116
k141_38438_2	megares|MEG_7340|Drugs|Glycopeptide|VanA-type_resistance_protein|VANA_1	35.0	286	320	346	3.28e-30	116
k141_38438_2	megares|MEG_7344|Drugs|Glycopeptide|VanA-type_resistance_protein|VANA_2	35.0	286	320	352	3.62e-30	116
k141_38438_2	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_5	34.2	263	320	281	4.98e-30	114
k141_38438_2	SARG|gb|MBY8651253.1|ARO:3007189|vanP	28.4	349	320	342	2.15e-28	111
k141_14857_2	SARG|YP_001176066	28.3	223	406	411	4.13e-11	63.2
k141_14857_2	SARG|gi|554963100|ref|WP_023207486.1|	26.0	169	406	413	4.15e-11	63.2
k141_14857_2	SARG|gi|1002473661|ref|WP_061389473.1|	26.0	169	406	413	4.15e-11	63.2
k141_14857_2	SARG|gi|1002474409|ref|WP_061389690.1|	26.0	169	406	413	4.15e-11	63.2
k141_14857_2	SARG|gi|447111661|ref|WP_001188917.1|	26.0	169	406	413	4.15e-11	63.2
k141_14857_2	SARG|gi|553877911|ref|WP_023139226.1|	26.0	169	406	413	4.15e-11	63.2
k141_14857_2	SARG|gi|1002390459|ref|WP_061377141.1|	26.0	169	406	413	4.15e-11	63.2
k141_14857_2	SARG|CP001138.1.gene4809.p01	26.0	169	406	413	4.15e-11	63.2
k141_14857_2	SARG|gi|447111665|ref|WP_001188921.1|	26.0	169	406	413	4.15e-11	63.2
k141_14857_2	SARG|YP_219359	26.0	169	406	413	4.15e-11	63.2
k141_2551_18	SARG|gb|APB03219.1|ARO:3003986|TaeA	34.2	657	618	648	3.76e-101	320
k141_2551_18	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	561	618	655	1.18e-58	207
k141_2551_18	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	561	618	655	1.18e-58	207
k141_2551_18	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	561	618	655	1.18e-58	207
k141_2551_18	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	561	618	655	1.18e-58	207
k141_2551_18	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	561	618	655	1.18e-58	207
k141_2551_18	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	561	618	655	1.63e-58	206
k141_2551_18	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	561	618	655	2.25e-58	206
k141_2551_18	SARG|gb|AKA86814|ARO:3003746|optrA	30.1	561	618	655	2.25e-58	206
k141_2551_18	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	561	618	655	3.11e-58	206
k141_2551_26	SARG|L42544.gene.p01	29.7	454	534	651	2.49e-39	150
k141_2551_26	SARG|AAV80410	29.7	454	534	651	2.49e-39	150
k141_2551_26	SARG|AJ514254.gene.p01	27.5	448	534	640	1.88e-36	142
k141_2551_26	SARG|NP_348076	27.6	449	534	652	1.86e-34	136
k141_2551_26	SARG|Q02652	27.2	452	534	639	6.25e-33	132
k141_2551_26	SARG|L20800.gene.p01	26.0	447	534	652	1.21e-32	131
k141_2551_26	SARG|YP_002850805	26.4	447	534	652	7.16e-32	129
k141_2551_26	SARG|ZP_02952732	25.7	447	534	652	9.63e-32	128
k141_2551_26	SARG|ZP_02632674	25.7	447	534	660	9.96e-32	128
k141_2551_26	SARG|CAA37477	27.9	462	534	663	8.30e-30	122
k141_68547_5	SARG|gi|949718947|ref|WP_057063453.1|	35.0	243	628	648	8.56e-24	105
k141_68547_5	SARG|gi|696368937|ref|WP_032943949.1|	35.1	239	628	648	1.14e-23	104
k141_68547_5	SARG|gi|851913025|ref|WP_048215946.1|	35.1	239	628	648	1.14e-23	104
k141_68547_5	SARG|gi|489930965|ref|WP_003834285.1|	35.1	239	628	648	1.14e-23	104
k141_68547_5	SARG|gi|851922185|ref|WP_048218206.1|	35.1	239	628	648	1.51e-23	104
k141_68547_5	SARG|gi|696375069|ref|WP_032949617.1|	35.1	239	628	648	1.51e-23	104
k141_68547_5	SARG|gi|696361545|ref|WP_032936694.1|	35.1	239	628	648	1.51e-23	104
k141_68547_5	SARG|gi|489936909|ref|WP_003840216.1|	35.1	239	628	648	1.51e-23	104
k141_68547_5	SARG|gi|489127020|ref|WP_003036815.1|	35.1	239	628	648	1.51e-23	104
k141_68547_5	SARG|gi|507079862|ref|WP_016150620.1|	35.1	239	628	648	1.51e-23	104
k141_79800_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	20.4	779	832	1024	3.44e-34	140
k141_79800_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	20.4	779	832	1024	3.44e-34	140
k141_79800_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	20.4	779	832	1024	1.05e-33	138
k141_79800_1	SARG|gb|CAA53189|ARO:3000521|mupA	20.4	779	832	1024	1.05e-33	138
k141_32014_5	SARG|gb|AAC74000.1|ARO:3003950|msbA	35.2	159	222	582	3.06e-16	75.9
k141_32014_5	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	26.7	202	222	505	4.65e-12	63.5
k141_32014_5	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	25.4	201	222	504	1.55e-11	62.0
k141_32014_5	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.8	156	222	575	9.82e-11	59.7
k141_32014_5	SARG|gb|AAK76136.1|ARO:3000025|patB	29.3	174	222	588	4.42e-10	57.8
k141_32014_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.1	155	222	664	9.04e-09	53.9
k141_32014_5	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	29.1	151	222	578	2.86e-08	52.4
k141_32014_5	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.7	165	222	579	6.97e-08	51.2
k141_32014_5	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.7	165	222	579	1.26e-07	50.4
k141_20411_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	29.6	115	205	231	2.58e-10	57.0
k141_20411_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	29.6	115	205	231	2.58e-10	57.0
k141_20411_4	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.1	118	205	231	6.62e-10	55.8
k141_20411_4	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.2	118	205	231	1.70e-09	54.7
k141_20411_4	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.4	118	205	231	1.10e-08	52.4
k141_20411_9	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	35.9	701	656	703	1.01e-111	350
k141_61988_11	SARG|gi|1035686596|ref|WP_064530178.1|	35.8	215	232	648	7.33e-25	101
k141_61988_11	SARG|gi|974672242|ref|WP_059256507.1|	38.3	180	232	648	1.35e-24	100
k141_61988_11	SARG|gi|974641719|ref|WP_059227752.1|	38.3	180	232	648	1.35e-24	100
k141_61988_11	SARG|gi|643601187|ref|WP_025237288.1|	38.3	180	232	648	1.35e-24	100
k141_61988_11	SARG|gi|974628291|ref|WP_059215695.1|	38.3	180	232	648	1.35e-24	100
k141_61988_11	SARG|gi|446110298|ref|WP_000188153.1|	38.3	180	232	648	1.35e-24	100
k141_61988_11	SARG|gi|446110299|ref|WP_000188154.1|	38.3	180	232	648	1.35e-24	100
k141_61988_11	SARG|ZP_02903696	38.3	180	232	648	1.35e-24	100
k141_61988_11	SARG|gi|974688082|ref|WP_059271287.1|	38.3	180	232	648	1.35e-24	100
k141_61988_11	SARG|gi|754732608|ref|WP_042101370.1|	37.2	180	232	648	3.39e-24	99.4
k141_61988_15	CARD|gb|BAB36671.1|ARO:3000832|evgA	26.9	212	221	204	1.49e-20	84.7
k141_61988_15	CARD|gb|AAG06465.1|ARO:3005063|cprR	36.0	89	221	223	1.77e-08	52.0
k141_8263_3	SARG|gb|AAP82271|ARO:3004123|Burkholderia	27.3	428	401	374	4.52e-21	92.8
k141_80077_3	CARD|gb|TKW44661.1|ARO:3005040|YajC	36.0	114	116	112	1.60e-16	68.6
k141_80077_8	SARG|gb|APB03219.1|ARO:3003986|TaeA	31.5	197	338	648	6.26e-11	62.4
k141_15754_6	CARD|gb|BAB38260.1|ARO:3000830|cpxA	30.6	108	728	457	3.23e-07	52.4
k141_86443_10	SARG|gi|1004359922|gb|AMP42228.1|	25.5	435	598	639	9.98e-30	123
k141_86443_10	SARG|ACI02041	25.3	434	598	639	1.35e-28	119
k141_86443_10	SARG|gi|1004359892|gb|AMP42199.1|	25.3	434	598	639	2.41e-28	119
k141_86443_10	SARG|CAO78565	25.3	434	598	639	2.41e-28	119
k141_86443_10	SARG|gi|254967129|gb|ACT97610.1|	25.3	434	598	639	3.21e-28	118
k141_86443_10	SARG|AJ222769.gene.p01	25.3	434	598	639	3.21e-28	118
k141_86443_10	SARG|gi|168258996|gb|ACA23181.1|	25.3	434	598	639	3.21e-28	118
k141_86443_10	SARG|AAY62597	25.3	434	598	639	3.21e-28	118
k141_86443_10	SARG|gi|1028100281|ref|WP_063856416.1|	25.3	434	598	639	3.21e-28	118
k141_86443_10	SARG|ACA23195	25.3	434	598	639	3.21e-28	118
k141_92661_1	SARG|gi|852273548|ref|WP_048328542.1|	29.1	609	643	1043	1.12e-50	188
k141_92661_1	SARG|YP_001668663	28.0	615	643	1043	8.98e-50	186
k141_92661_1	SARG|YP_608682	30.7	492	643	1042	2.93e-49	184
k141_92661_1	SARG|gi|951155204|ref|WP_057635531.1|	27.3	598	643	1047	3.97e-49	184
k141_92661_1	SARG|gi|951157033|ref|WP_057637070.1|	27.7	600	643	1046	9.63e-49	182
k141_92661_1	SARG|gi|685985107|ref|WP_031691711.1|	28.2	609	643	1043	1.29e-48	182
k141_92661_1	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	27.0	626	643	1051	1.30e-48	182
k141_92661_1	SARG|gi|499256187|ref|WP_010953727.1|	30.8	490	643	1042	1.73e-48	182
k141_92661_1	SARG|gi|553771491|ref|WP_023103521.1|	28.1	609	643	1043	1.73e-48	182
k141_92661_1	SARG|YP_348488	27.1	616	643	1043	1.73e-48	182
k141_32892_13	SARG|gb|ADZ12699.1|ARO:3005091|RanA	28.4	236	272	258	1.74e-32	119
k141_32892_13	SARG|gi|921979807|ref|WP_053271336.1|	30.5	259	272	648	6.00e-20	88.2
k141_32892_13	SARG|gi|585358510|ref|WP_024240108.1|	30.5	259	272	648	1.10e-19	87.4
k141_32892_13	SARG|gb|AAK76136.1|ARO:3000025|patB	23.8	235	272	588	5.58e-14	70.5
k141_32892_13	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.4	230	272	664	1.06e-13	69.7
k141_32892_13	SARG|gb|CDO61516.1|ARO:3003949|efrB	24.6	211	272	362	1.29e-09	57.0
k141_32892_13	SARG|gb|AVI44920.1|ARO:3004470|poxtA	26.9	197	272	542	5.55e-07	49.3
k141_32892_13	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	26.9	197	272	544	5.56e-07	49.3
k141_32892_13	SARG|AXF35727.1	25.2	210	272	497	7.20e-06	45.8
k141_9026_1	CARD|gb|AEX49906.1|ARO:3003583|basS	27.0	241	729	477	2.09e-08	56.2
k141_9026_1	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	21.8	243	729	359	1.83e-06	49.7
k141_9026_1	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	21.5	274	729	364	3.25e-06	48.9
k141_9026_1	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	21.5	274	729	364	3.25e-06	48.9
k141_9026_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	34.4	122	287	225	9.24e-15	70.9
k141_9026_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.6	122	287	225	3.28e-14	69.3
k141_9026_2	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	27.8	115	287	225	2.31e-11	61.2
k141_9026_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	29.2	120	287	229	1.62e-07	50.1
k141_92954_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.4	177	390	370	1.31e-13	70.5
k141_92954_3	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.8	179	390	365	7.62e-11	62.0
k141_21266_2	CARD|gb|AEX49906.1|ARO:3003583|basS	31.5	292	542	477	6.12e-23	100
k141_56851_3	CARD|gb|BAB36671.1|ARO:3000832|evgA	22.0	150	222	204	1.13e-06	46.6
k141_80827_2	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.7	215	550	293	2.05e-16	79.0
k141_80827_8	CARD|gb|AAG06465.1|ARO:3005063|cprR	37.7	223	225	223	3.55e-47	154
k141_93144_3	CARD|gb|AIA35096.1|ARO:3005059|LptD	30.1	549	609	782	5.02e-66	229
k141_21525_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.9	209	216	228	3.33e-37	128
k141_21525_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.3	204	216	232	1.46e-36	127
k141_21525_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.3	204	216	232	1.46e-36	127
k141_21525_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.2	199	216	219	3.07e-32	115
k141_21525_4	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.3	201	216	219	6.08e-32	114
k141_21525_4	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.3	201	216	220	6.23e-32	114
k141_21525_4	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.3	201	216	220	6.23e-32	114
k141_21525_4	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.1	205	216	230	1.58e-31	114
k141_21525_4	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.8	201	216	219	4.73e-31	112
k141_21525_4	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.3	201	216	220	4.84e-31	112
k141_57033_2	megares|MEG_8288|Drugs|beta-lactam|Mutant_porin_proteins|OMPA_1	43.4	136	223	374	8.24e-26	102
k141_57033_2	CARD|gb|CDO13836.1|ARO:3005044|OmpA	43.4	136	223	374	8.24e-26	102
k141_33379_2	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	47.3	1037	1034	1051	1.86e-308	882
k141_33379_2	CARD|gb|ABS43151.1|ARO:3000784|cmeB	44.4	1037	1034	1040	6.07e-293	842
k141_33379_2	NCBI|WP_254563251.1|1|1|cmeB_RE|cmeB_RE|efflux|2|FLORFENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_CmeB,_ciprofloxacin_and_phenicol_resistance_type|AMR|multidrug	44.1	1042	1034	1039	1.64e-278	805
k141_33379_2	CARD|gb|BAA16344.1|ARO:3000491|acrD	43.8	1034	1034	1037	5.06e-271	786
k141_33379_2	SARG|gi|817604860|ref|WP_046598079.1|	42.6	1034	1034	1037	3.69e-259	755
k141_33379_2	SARG|gi|694076105|ref|WP_032421853.1|	42.6	1035	1034	1036	7.15e-259	754
k141_33379_2	SARG|gi|556290479|ref|WP_023291164.1|	42.6	1035	1034	1036	2.01e-258	753
k141_33379_2	SARG|gi|496667122|ref|WP_009309612.1|	42.5	1035	1034	1036	2.01e-258	753
k141_33379_2	SARG|CP000647.1.gene3710.p01	42.6	1031	1034	1036	2.85e-258	753
k141_33379_2	SARG|gi|817600173|ref|WP_046594139.1|	42.6	1034	1034	1037	2.94e-258	753
k141_33379_3	NCBI|AAA80193.1|1|1|mtrC|mtrC|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_MtrC|AMR|efflux	29.6	355	368	412	1.29e-26	108
k141_33379_3	SARG|YP_001882199	26.5	366	368	385	3.32e-26	107
k141_33379_3	SARG|gi|754615047|ref|WP_042004421.1|	26.8	366	368	385	4.56e-26	106
k141_33379_3	SARG|gi|545247736|ref|WP_021546171.1|	26.8	366	368	385	4.56e-26	106
k141_33379_3	SARG|gi|447004743|ref|WP_001081999.1|	26.5	366	368	385	4.56e-26	106
k141_33379_3	SARG|gi|447004721|ref|WP_001081977.1|	26.5	366	368	385	6.25e-26	106
k141_33379_3	SARG|gi|566279833|gb|ETJ23359.1|	26.5	366	368	385	6.25e-26	106
k141_33379_3	SARG|gi|391257401|gb|EIQ16513.1|	26.5	366	368	385	6.25e-26	106
k141_33379_3	SARG|gi|657329748|ref|WP_029396991.1|	26.5	366	368	385	6.25e-26	106
k141_33379_3	SARG|gi|486394471|ref|WP_001604024.1|	26.2	366	368	385	6.25e-26	106
k141_76352_4	SARG|AF462611.1.orf0.gene.p01	29.8	258	266	281	3.72e-18	80.9
k141_76352_4	SARG|P07287	33.7	181	266	381	1.75e-17	80.1
k141_76352_4	megares|MEG_2827|Drugs|MLS|23S_rRNA_methyltransferases|ERME_1	33.7	181	266	381	1.75e-17	80.1
k141_76352_4	SARG|AAA22075	30.6	232	266	340	1.17e-16	77.4
k141_76352_4	NCBI|WP_129546809.1|1|1|erm(56)|erm(56)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/PRISTINAMYCIN|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(56)|AMR|multidrug	31.4	204	266	266	8.69e-15	71.2
k141_76352_4	SARG|1112175A	34.7	150	266	370	4.73e-14	70.1
k141_76352_4	SARG|AAA26492	34.0	150	266	370	7.15e-13	66.6
k141_76352_4	megares|MEG_2826|Drugs|MLS|23S_rRNA_methyltransferases|ERME_1	34.0	150	266	370	7.15e-13	66.6
k141_76352_4	SARG|AF079138.1.orf0.gene.p01	31.7	186	266	322	9.77e-11	60.1
k141_76376_23	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	42.3	220	234	225	1.41e-49	160
k141_76376_23	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	35.6	239	234	252	1.30e-41	141
k141_76376_23	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.1	221	234	228	1.52e-40	137
k141_76376_23	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.4	223	234	231	3.63e-39	134
k141_76376_23	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	32.2	227	234	231	1.12e-37	130
k141_76376_23	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.2	227	234	231	1.12e-37	130
k141_76376_23	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.1	225	234	229	2.12e-37	129
k141_76376_23	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.9	225	234	231	4.43e-37	129
k141_76376_23	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.9	225	234	231	6.25e-37	128
k141_76376_23	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.9	225	234	231	6.25e-37	128
k141_76376_24	SARG|gi|544780240|ref|WP_021203903.1|	29.1	467	475	461	2.05e-33	130
k141_76376_24	SARG|CAG34266	28.4	464	475	474	4.53e-33	129
k141_76376_24	SARG|CAC14596	28.7	467	475	466	2.67e-32	127
k141_76376_24	SARG|YP_002706078	28.9	467	475	481	3.19e-32	127
k141_76376_24	SARG|CAG34251	28.7	467	475	466	4.98e-32	126
k141_76376_24	SARG|YP_001973746	28.4	458	475	466	6.80e-32	126
k141_76376_24	SARG|gi|491553496|ref|WP_005411087.1|	28.4	458	475	461	8.75e-32	125
k141_76376_24	SARG|NC_008702.1.4608931.p01	28.1	474	475	473	3.48e-31	124
k141_76376_24	SARG|NC_011035.1.6449630.p01	29.5	421	475	467	2.10e-28	116
k141_76376_24	SARG|gi|488170688|ref|WP_002241896.1|	29.7	411	475	467	5.24e-28	115
k141_76376_25	SARG|gi|490848588|ref|WP_004710651.1|	27.0	418	434	446	2.88e-29	117
k141_76376_25	SARG|gi|487980711|ref|WP_002053440.1|	26.8	418	434	446	9.99e-29	116
k141_76376_25	SARG|gi|518287882|ref|WP_019458090.1|	26.2	401	434	446	3.00e-27	112
k141_76376_25	SARG|gi|947821497|ref|WP_056482838.1|	25.0	400	434	446	2.50e-24	103
k141_76376_25	SARG|gi|507071439|ref|WP_016142217.1|	25.7	401	434	445	4.55e-24	102
k141_76376_25	SARG|gi|949737715|ref|WP_057075721.1|	25.2	424	434	445	6.15e-24	102
k141_76376_25	SARG|gi|770625864|ref|WP_045126264.1|	24.8	400	434	446	6.20e-24	102
k141_76376_25	SARG|gi|780007567|ref|WP_045435047.1|	24.8	400	434	446	8.39e-24	102
k141_76376_25	SARG|gi|489750934|ref|WP_003654943.1|	24.8	400	434	446	8.39e-24	102
k141_76376_25	SARG|gi|496866281|ref|WP_009390736.1|	25.7	401	434	445	1.13e-23	101
k141_76376_26	SARG|gi|495736522|ref|WP_008461101.1|	49.1	222	241	648	4.34e-60	199
k141_76376_26	SARG|gi|746253210|ref|WP_039301529.1|	48.6	222	241	648	1.64e-59	197
k141_76376_26	SARG|gi|803568669|ref|WP_046077412.1|	48.2	222	241	648	2.29e-59	197
k141_76376_26	SARG|gi|446110352|ref|WP_000188207.1|	48.2	222	241	648	2.29e-59	197
k141_76376_26	SARG|YP_002382193	48.2	222	241	648	2.29e-59	197
k141_76376_26	SARG|gi|803575554|ref|WP_046081557.1|	48.2	222	241	648	2.29e-59	197
k141_76376_26	SARG|gi|446110351|ref|WP_000188206.1|	48.2	222	241	648	2.29e-59	197
k141_76376_26	SARG|gi|639225329|ref|WP_024561799.1|	45.5	235	241	648	3.20e-59	196
k141_76376_26	SARG|gi|639218559|ref|WP_024556062.1|	45.5	235	241	648	3.20e-59	196
k141_76376_26	SARG|gi|974588181|ref|WP_059178476.1|	46.3	229	241	646	4.33e-59	196
k141_76376_27	SARG|gi|487359045|ref|WP_001634240.1|	35.9	401	403	648	2.47e-62	211
k141_76376_27	SARG|gi|485890120|ref|WP_001482667.1|	35.9	401	403	648	2.47e-62	211
k141_76376_27	SARG|gi|487574794|ref|WP_001721241.1|	35.9	401	403	648	3.43e-62	210
k141_76376_27	SARG|gi|754731641|ref|WP_042100724.1|	35.9	401	403	648	4.78e-62	210
k141_76376_27	SARG|gi|487410704|ref|WP_001678420.1|	35.9	401	403	648	4.78e-62	210
k141_76376_27	SARG|gi|446110321|ref|WP_000188176.1|	35.9	401	403	648	6.66e-62	209
k141_76376_27	SARG|gi|485866062|ref|WP_001464282.1|	35.9	401	403	648	6.66e-62	209
k141_76376_27	SARG|gi|693138751|ref|WP_032280630.1|	35.9	401	403	648	9.27e-62	209
k141_76376_27	SARG|gi|693170426|ref|WP_032302787.1|	35.9	401	403	648	9.27e-62	209
k141_76376_27	SARG|gi|485860032|ref|WP_001459624.1|	35.9	401	403	648	9.27e-62	209
k141_76376_29	SARG|gb|AAD08227.1|ARO:3003964|hp1181	33.2	385	405	443	4.65e-46	163
k141_76376_29	SARG|gi|695688999|ref|WP_032634100.1|	32.7	104	405	404	3.77e-08	53.9
k141_76376_30	SARG|gb|ABX00624.1|ARO:3002881|lmrC	37.4	91	931	550	1.28e-07	54.3
k141_76376_30	SARG|gi|671541568|ref|WP_031525212.1|	33.0	100	931	648	7.22e-07	52.0
k141_57184_2	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	37.9	330	340	379	1.90e-55	184
k141_57184_2	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	37.9	330	340	416	4.58e-55	184
k141_57184_2	SARG|CP001581.1.gene3143.p01	35.5	318	340	344	2.68e-48	164
k141_57184_2	SARG|gb|CAL84423.1|ARO:3004146|cfrC	37.1	286	340	344	7.42e-48	163
k141_57184_2	SARG|gb|AGZ55247.1|ARO:3002814|clbA	34.4	320	340	349	2.46e-46	159
k141_57184_2	SARG|gb|BAD63613.1|ARO:3002816|clbC	34.4	323	340	350	8.19e-43	150
k141_57184_2	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	35.0	286	340	349	8.41e-42	147
k141_57184_2	SARG|AJ249217.gene.p01	35.0	286	340	349	2.30e-41	146
k141_57184_2	SARG|VXQ21601.1	33.5	322	340	344	2.24e-39	141
k141_33464_2	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.4	194	286	343	8.02e-22	92.4
k141_33464_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	25.5	212	286	307	2.54e-17	79.3
k141_33464_2	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	30.1	196	286	293	3.67e-16	75.9
k141_33464_2	SARG|gb|AAA26793|ARO:3003748|oleC	27.9	208	286	325	1.08e-14	72.0
k141_33464_2	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	27.9	208	286	325	1.08e-14	72.0
k141_33464_2	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.2	210	286	574	2.11e-14	72.0
k141_33464_2	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.1	226	286	648	6.32e-11	61.6
k141_33464_2	SARG|gb|AAR96051.1|ARO:3002894|otrC	29.9	117	286	351	1.51e-08	53.9
k141_33464_2	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	29.9	117	286	351	1.51e-08	53.9
k141_9854_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	36.3	416	423	648	1.04e-75	247
k141_9854_1	SARG|M80346.gene.p01	34.8	431	423	551	3.27e-47	169
k141_9854_1	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	34.8	431	423	551	3.27e-47	169
k141_9854_1	SARG|X63451.gene.p01	31.6	446	423	550	2.94e-44	160
k141_9854_1	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	31.6	446	423	550	2.94e-44	160
k141_9854_1	SARG|gb|NP_388442.1|ARO:3004476|vmlR	29.4	412	423	547	5.29e-35	135
k141_9854_1	SARG|gb|AGN74946|ARO:3003749|salA	25.7	412	423	541	5.63e-31	123
k141_9854_1	SARG|gb|MBW0764195.1|ARO:3007027|salC	27.1	284	423	541	1.58e-27	113
k141_9854_1	SARG|gb|MBW0770001.1|ARO:3007026|salB	27.3	421	423	541	2.14e-27	113
k141_9854_1	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	31.7	243	423	524	1.18e-23	102
k141_81323_10	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	37.9	219	219	231	2.60e-44	147
k141_81323_10	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.2	217	219	219	5.25e-44	145
k141_81323_10	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.2	217	219	219	7.42e-44	145
k141_81323_10	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.2	217	219	220	7.63e-44	145
k141_81323_10	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.4	219	219	219	1.48e-43	144
k141_81323_10	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	37.9	219	219	233	2.18e-43	144
k141_81323_10	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.7	217	219	220	3.04e-43	144
k141_81323_10	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.2	217	219	220	1.92e-41	139
k141_81323_10	SARG|ZP_02848503	38.7	217	219	221	2.20e-40	136
k141_81323_10	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.7	221	219	223	1.03e-38	132
k141_81323_11	CARD|gb|AEX49906.1|ARO:3003583|basS	32.9	450	449	477	1.17e-67	222
k141_81323_11	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.6	233	449	361	1.16e-16	80.1
k141_4285_3	NCBI|WP_281052475.1|1|1|mcr-4.9|mcr-4||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-4.9|AMR|peptide	33.7	540	632	541	8.25e-94	298
k141_4285_3	SARG|gb|WP_001572373.1|ARO:3004684|MCR-9	36.9	445	632	539	1.10e-93	298
k141_4285_3	NCBI|MBO4175406.1|1|1|mcr-9.2|mcr-9||1|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-9.2|AMR|peptide	36.9	445	632	540	1.13e-93	298
k141_4285_3	NCBI|QKF95689.1|1|1|mcr-9.3|mcr-9||1|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-9.3|AMR|peptide	36.9	445	632	539	1.54e-93	297
k141_4285_3	SARG|gb|AVK94779.1|ARO:3004696|MCR-4.4	34.5	534	632	541	4.50e-93	296
k141_4285_3	megares|MEG_3730|Drugs|Lipopeptide|Colistin_phosphoethanolamine_transferase|MCR_1	34.5	534	632	541	4.50e-93	296
k141_4285_3	SARG|gb|AVK94777.1|ARO:3004694|MCR-4.2	34.5	534	632	541	8.87e-93	295
k141_4285_3	megares|MEG_3715|Drugs|Lipopeptide|Colistin_phosphoethanolamine_transferase|MCR_1	34.5	534	632	541	8.87e-93	295
k141_4285_3	megares|MEG_3728|Drugs|Lipopeptide|Colistin_phosphoethanolamine_transferase|MCR_1	34.5	534	632	541	8.87e-93	295
k141_4285_3	SARG|ASR73329.1	34.5	534	632	541	8.87e-93	295
k141_57587_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	29.3	123	216	247	6.03e-12	62.0
k141_57587_2	CARD|gb|AAG05188.1|ARO:3005068|ParR	24.6	142	216	235	3.36e-08	51.2
k141_63637_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	37.2	562	587	582	1.95e-120	367
k141_63637_4	SARG|gi|648667297|ref|WP_026359044.1|	33.1	571	587	605	2.42e-89	287
k141_63637_4	SARG|gi|928900436|ref|WP_053931243.1|	33.3	571	587	600	4.21e-89	286
k141_63637_4	SARG|gi|664579989|ref|WP_031094015.1|	33.3	571	587	601	4.32e-89	286
k141_63637_4	SARG|gi|948137056|ref|WP_056795395.1|	33.3	571	587	602	1.71e-88	285
k141_63637_4	SARG|gi|1045390184|ref|WP_065479071.1|	32.8	582	587	605	2.58e-88	284
k141_63637_4	SARG|gi|944152509|ref|WP_055644808.1|	33.3	573	587	616	6.63e-88	283
k141_63637_4	SARG|gi|516795764|ref|WP_018105258.1|	32.9	571	587	601	9.03e-88	283
k141_63637_4	SARG|gi|505420018|ref|WP_015607120.1|	33.7	570	587	603	9.48e-88	283
k141_63637_4	SARG|gi|827013130|ref|WP_047175495.1|	33.3	571	587	603	1.33e-87	282
k141_63637_5	SARG|gb|AAC74000.1|ARO:3003950|msbA	36.2	495	510	582	1.86e-107	331
k141_63637_5	SARG|gi|739906046|ref|WP_037756452.1|	30.0	503	510	620	1.40e-73	243
k141_63637_5	SARG|gi|948137056|ref|WP_056795395.1|	30.3	501	510	602	1.87e-73	243
k141_63637_5	SARG|gi|648667297|ref|WP_026359044.1|	30.0	506	510	605	2.79e-73	242
k141_63637_5	SARG|gi|558888514|ref|WP_023543283.1|	30.3	498	510	615	3.45e-73	242
k141_63637_5	SARG|gi|516574297|ref|WP_017949361.1|	29.8	503	510	620	7.48e-73	241
k141_63637_5	SARG|AF170880.4.gene1.p01	30.1	498	510	615	1.31e-72	241
k141_63637_5	SARG|gi|947982677|ref|WP_056642336.1|	30.2	507	510	626	3.22e-72	240
k141_63637_5	SARG|gi|928900436|ref|WP_053931243.1|	29.8	497	510	600	5.10e-72	239
k141_63637_5	SARG|gi|664579989|ref|WP_031094015.1|	29.8	497	510	601	5.21e-72	239
k141_63835_1	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	32.4	74	166	225	6.88e-06	43.5
k141_29130_1	CARD|gb|AAG06465.1|ARO:3005063|cprR	39.6	222	235	223	3.88e-49	159
k141_29130_1	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	36.8	234	235	252	1.41e-33	120
k141_29130_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.6	232	235	228	1.70e-32	117
k141_29130_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.9	186	235	232	2.69e-27	103
k141_29130_1	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.4	225	235	235	3.20e-25	98.2
k141_29130_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.6	230	235	219	3.35e-24	95.1
k141_47069_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	27.9	588	745	1024	1.04e-58	214
k141_47069_1	SARG|gb|CAA53189|ARO:3000521|mupA	27.9	588	745	1024	1.04e-58	214
k141_47069_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	27.9	588	745	1024	1.41e-58	214
k141_47069_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	27.9	588	745	1024	1.41e-58	214
k141_47069_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	28.0	583	745	1033	1.91e-55	204
k141_47069_1	SARG|gb|AEY83581|ARO:3000510|mupB	28.0	583	745	1033	1.91e-55	204
k141_47069_1	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	26.3	631	745	1107	2.19e-50	189
k141_47069_1	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	26.3	631	745	1107	2.19e-50	189
k141_87865_3	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	42.1	850	852	1051	8.85e-201	599
k141_87865_3	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	40.7	855	852	1074	1.74e-189	570
k141_87865_3	SARG|gi|757680562|ref|WP_042911120.1|	41.1	854	852	1043	2.36e-184	556
k141_87865_3	SARG|gi|686100357|ref|WP_031756979.1|	41.1	854	852	1043	2.36e-184	556
k141_87865_3	SARG|gi|685982963|ref|WP_031690166.1|	41.1	854	852	1043	3.32e-184	556
k141_87865_3	SARG|gi|685985107|ref|WP_031691711.1|	41.1	854	852	1043	3.32e-184	556
k141_87865_3	SARG|gi|759350549|ref|WP_043081214.1|	41.1	854	852	1043	3.32e-184	556
k141_87865_3	SARG|gi|685890627|ref|WP_031631929.1|	41.0	854	852	1043	9.28e-184	555
k141_87865_3	SARG|gi|489226605|ref|WP_003134989.1|	41.0	854	852	1043	9.28e-184	555
k141_87865_3	SARG|CAW29737	41.0	854	852	1043	9.28e-184	555
k141_22073_2	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	39.7	232	291	343	2.09e-46	158
k141_22073_2	SARG|gb|AAA26793|ARO:3003748|oleC	33.6	223	291	325	1.00e-35	129
k141_22073_2	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	33.6	223	291	325	1.00e-35	129
k141_22073_2	SARG|gb|AAR96051.1|ARO:3002894|otrC	29.7	229	291	351	5.49e-23	95.9
k141_22073_2	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	29.3	229	291	351	3.72e-22	93.6
k141_64243_1	ResF|penA_1_AF515059_1	42.9	163	178	581	1.42e-36	132
k141_64243_3	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	34.6	286	319	481	1.63e-28	113
k141_64243_3	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	36.8	209	319	451	4.44e-28	112
k141_64243_3	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	34.4	291	319	451	8.36e-28	111
k141_41416_9	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	38.5	221	622	343	8.74e-39	145
k141_41416_9	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	39.4	198	622	293	9.14e-32	124
k141_41416_9	SARG|gb|AAA26793|ARO:3003748|oleC	29.3	314	622	325	3.75e-26	108
k141_41416_9	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	29.3	314	622	325	3.75e-26	108
k141_41416_9	SARG|gi|445996719|ref|WP_000074574.1|	33.0	191	622	309	1.29e-25	106
k141_41416_9	SARG|gi|542061059|gb|ERI11611.1|	33.0	191	622	316	1.46e-25	106
k141_41416_9	SARG|gi|445996708|ref|WP_000074563.1|	33.0	221	622	309	1.74e-25	106
k141_41416_9	SARG|gi|446026113|ref|WP_000103968.1|	31.3	192	622	306	2.23e-25	105
k141_41416_9	SARG|gi|445996729|ref|WP_000074584.1|	33.0	191	622	309	2.36e-25	105
k141_41416_9	SARG|gi|445996710|ref|WP_000074565.1|	33.0	191	622	309	2.36e-25	105
k141_77109_6	SARG|YP_001175678	47.6	374	408	397	1.16e-98	298
k141_77109_6	SARG|ABR13270	47.3	374	408	397	1.16e-98	298
k141_77109_6	SARG|ABG77965	47.9	374	408	397	1.16e-98	298
k141_77109_6	SARG|gi|749018243|ref|WP_040076872.1|	47.6	374	408	397	4.64e-98	297
k141_77109_6	SARG|gi|503835165|ref|WP_014069159.1|	47.9	374	408	397	1.85e-97	295
k141_77109_6	SARG|gi|928884686|ref|WP_053919771.1|	47.3	374	408	397	5.23e-97	294
k141_77109_6	SARG|YP_002401592	47.3	374	408	397	7.40e-97	294
k141_77109_6	SARG|gi|928844224|ref|WP_053895298.1|	47.3	374	408	397	1.05e-96	293
k141_77109_6	SARG|CAS07946	47.3	374	408	397	1.05e-96	293
k141_77109_6	SARG|NC_002695.1.914620.p01	47.3	374	408	397	1.05e-96	293
k141_77109_7	SARG|CAW25151	57.3	1051	1052	1046	0.0	1122
k141_77109_7	SARG|gi|237823426|pdb|2V50|A	57.3	1051	1052	1052	0.0	1122
k141_77109_7	SARG|NC_002516.2.877852.p01	57.3	1051	1052	1046	0.0	1122
k141_77109_7	SARG|YP_001345921	57.8	1035	1052	1046	0.0	1120
k141_77109_7	SARG|gi|489234352|ref|WP_003142649.1|	57.2	1051	1052	1046	0.0	1120
k141_77109_7	SARG|gb|AAA74437.1|ARO:3000378|MexB	57.2	1051	1052	1046	0.0	1120
k141_77109_7	SARG|gi|489213017|ref|WP_003121760.1|	57.3	1051	1052	1046	0.0	1120
k141_77109_7	SARG|gi|552491341|gb|ERX48481.1|	58.1	1026	1052	1046	0.0	1115
k141_77109_7	SARG|YP_002089536	56.7	1051	1052	1046	0.0	1106
k141_77109_7	SARG|gi|505288054|ref|WP_015475156.1|	57.4	1035	1052	1046	0.0	1100
k141_77109_8	SARG|NC_008702.1.4606278.p01	48.1	457	476	467	2.50e-128	379
k141_77109_8	NCBI|AAY90615.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	45.9	479	476	486	4.96e-113	341
k141_77109_8	NCBI|AAQ92182.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	44.9	479	476	486	2.79e-109	331
k141_77109_8	SARG|YP_002083353	48.5	410	476	485	1.20e-104	319
k141_77109_8	SARG|gi|553749675|ref|WP_023082630.1|	48.4	409	476	485	6.70e-104	317
k141_77109_8	SARG|NC_002516.2.877851.p01	48.4	409	476	485	6.70e-104	317
k141_77109_8	SARG|YP_001345922	48.2	409	476	485	2.66e-103	316
k141_77109_8	SARG|gi|544780240|ref|WP_021203903.1|	44.0	461	476	461	3.67e-103	315
k141_77109_8	SARG|gi|553757603|ref|WP_023090259.1|	48.2	409	476	485	3.75e-103	315
k141_77109_8	SARG|CAC14596	43.7	460	476	466	2.39e-102	313
k141_5563_6	SARG|AAA50325	34.5	174	244	569	1.79e-11	62.4
k141_5563_6	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	29.7	202	244	524	8.24e-10	57.4
k141_5563_6	SARG|FR772051.1.gene9.p01	30.8	198	244	524	1.11e-09	57.0
k141_5563_6	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	28.1	199	244	522	4.00e-07	49.3
k141_5563_6	SARG|DQ823382.1.gene1.p01	28.1	199	244	522	4.00e-07	49.3
k141_5563_6	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	28.1	199	244	522	4.00e-07	49.3
k141_5563_6	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	28.1	199	244	522	4.00e-07	49.3
k141_5563_6	SARG|AAF24091	28.1	199	244	522	4.00e-07	49.3
k141_5563_6	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	28.1	199	244	522	4.00e-07	49.3
k141_5563_6	SARG|YP_002332257	28.1	199	244	522	4.00e-07	49.3
k141_22377_2	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	37.0	289	339	533	7.78e-47	165
k141_53481_2	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.2	252	373	355	1.50e-12	67.0
k141_53481_2	SARG|BAE96115	30.2	252	373	355	1.50e-12	67.0
k141_53481_2	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.8	248	373	356	2.08e-11	63.5
k141_53481_2	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	31.3	182	373	209	4.69e-08	52.0
k141_53597_2	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	40.3	238	291	252	4.16e-43	147
k141_53597_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	39.6	250	291	229	1.74e-42	144
k141_53597_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.7	243	291	228	1.85e-41	142
k141_53597_2	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	36.3	240	291	225	4.79e-37	130
k141_53597_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.8	240	291	231	8.52e-36	127
k141_53597_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.1	241	291	232	2.42e-35	126
k141_53597_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.1	241	291	232	2.42e-35	126
k141_53597_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.4	240	291	232	4.77e-35	125
k141_53597_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	36.0	247	291	247	6.95e-35	125
k141_53597_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.2	240	291	219	1.86e-34	123
k141_89049_2	CARD|gb|ABV18113.1|ARO:3001329|mdtG	30.7	394	529	408	7.27e-64	213
k141_89049_2	SARG|gi|488439534|ref|WP_002508919.1|	25.7	354	529	388	8.77e-16	78.2
k141_89049_2	SARG|gi|821514643|ref|WP_046837150.1|	25.7	393	529	386	2.06e-15	77.0
k141_89049_2	SARG|gi|757193207|ref|WP_042738170.1|	26.8	362	529	386	2.75e-15	76.6
k141_89049_2	SARG|gi|881076539|ref|WP_048792533.1|	25.4	382	529	388	2.79e-15	76.6
k141_89049_2	SARG|gi|446964030|ref|WP_001041286.1|	24.0	354	529	388	3.72e-15	76.3
k141_89049_2	SARG|gi|446964071|ref|WP_001041327.1|	24.6	357	529	388	4.97e-15	75.9
k141_89049_2	SARG|gi|686377301|ref|WP_031898500.1|	24.0	354	529	385	6.51e-15	75.5
k141_89049_2	SARG|gi|960864478|ref|WP_058342571.1|	24.0	354	529	388	6.63e-15	75.5
k141_89049_2	SARG|gi|446964025|ref|WP_001041281.1|	24.0	354	529	388	6.63e-15	75.5
k141_82577_2	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	19.1	748	880	1024	4.33e-11	65.9
k141_82577_2	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	19.1	748	880	1024	4.33e-11	65.9
k141_82577_2	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	19.1	748	880	1024	4.33e-11	65.9
k141_82577_2	SARG|gb|CAA53189|ARO:3000521|mupA	19.1	748	880	1024	4.33e-11	65.9
k141_82577_2	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	24.1	195	880	1107	1.56e-07	54.3
k141_82577_2	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	24.1	195	880	1107	1.56e-07	54.3
k141_11766_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	36.4	549	552	582	2.37e-124	376
k141_11766_2	SARG|gi|663330365|ref|WP_030329892.1|	31.2	548	552	607	1.68e-80	263
k141_11766_2	SARG|gi|764446018|ref|WP_044369325.1|	30.7	548	552	605	2.24e-80	262
k141_11766_2	SARG|gi|948137056|ref|WP_056795395.1|	31.7	546	552	602	2.93e-80	262
k141_11766_2	SARG|gi|827013130|ref|WP_047175495.1|	31.2	548	552	603	4.19e-80	261
k141_11766_2	SARG|gi|663155409|ref|WP_030194633.1|	31.0	548	552	605	4.39e-80	261
k141_11766_2	SARG|gi|664538723|ref|WP_031054357.1|	31.0	548	552	605	4.39e-80	261
k141_11766_2	SARG|gi|951183771|ref|WP_057661487.1|	31.0	548	552	603	8.21e-80	261
k141_11766_2	SARG|gi|505420018|ref|WP_015607120.1|	31.0	545	552	603	8.21e-80	261
k141_11766_2	SARG|gi|664317010|ref|WP_030845774.1|	31.0	548	552	605	8.60e-80	261
k141_94773_7	CARD|gb|BAB36671.1|ARO:3000832|evgA	19.2	213	243	204	4.82e-08	50.8
k141_23320_1	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.4	107	117	639	2.40e-16	72.4
k141_23320_2	SARG|L42544.gene.p01	28.5	670	701	651	1.55e-80	268
k141_23320_2	SARG|AAV80410	28.4	670	701	651	1.57e-79	265
k141_23320_2	SARG|YP_002850805	27.7	686	701	652	6.02e-79	264
k141_23320_2	SARG|NP_348076	26.8	682	701	652	1.17e-78	263
k141_23320_2	SARG|ZP_02952732	27.7	686	701	652	4.37e-78	261
k141_23320_2	SARG|ZP_02632674	27.7	686	701	660	5.19e-78	261
k141_23320_2	SARG|L20800.gene.p01	27.7	686	701	652	1.64e-77	260
k141_23320_2	SARG|AJ514254.gene.p01	26.4	683	701	640	4.70e-71	242
k141_23320_2	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.5	663	701	641	3.36e-69	237
k141_23320_2	SARG|AAZ79478	26.5	663	701	657	4.58e-69	237
k141_23320_6	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	42.6	1387	1388	1186	0.0	1023
k141_23320_6	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	42.6	1387	1388	1186	0.0	1023
k141_23320_6	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	43.5	1383	1388	1162	0.0	1019
k141_23492_1	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.4	107	117	639	3.28e-16	72.0
k141_23492_12	megares|MEG_7023|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETA_1	36.2	387	405	393	2.54e-62	204
k141_23492_12	SARG|AY264780.2.gene3.p01	36.2	387	405	393	2.54e-62	204
k141_23492_12	megares|MEG_6987|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TET39_1	35.2	392	405	395	4.70e-59	196
k141_23492_12	SARG|AY743590.gene.p01	35.2	392	405	395	4.70e-59	196
k141_23492_12	ResF|tet(39)_2_CP044518_1	34.9	392	405	395	1.82e-58	194
k141_23492_12	SARG|AAR96043	34.0	373	405	396	1.43e-57	192
k141_23492_12	SARG|AF090987.gene.p01	33.9	392	405	394	3.75e-57	191
k141_23492_12	SARG|gi|692960352|ref|WP_032153701.1|	35.1	373	405	399	1.64e-56	189
k141_23492_12	megares|MEG_8715|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TET64_1	35.9	354	405	396	2.14e-56	189
k141_23492_12	NCBI|WP_124470450.1|1|1|tet(64)|tet(64)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_MFS_transporter_Tet(64)|AMR|tetracycline	35.9	354	405	396	2.14e-56	189
k141_82821_2	SARG|gi|823326845|ref|WP_047080664.1|	41.0	222	254	648	1.69e-44	157
k141_82821_2	SARG|gi|1022688710|ref|WP_063443532.1|	41.4	222	254	648	1.69e-44	157
k141_82821_2	SARG|gi|823291602|ref|WP_047047573.1|	41.0	222	254	648	3.23e-44	156
k141_82821_2	SARG|gi|823302270|ref|WP_047057473.1|	41.0	222	254	648	3.23e-44	156
k141_82821_2	SARG|gi|976146774|ref|WP_059305359.1|	41.0	222	254	648	3.23e-44	156
k141_82821_2	SARG|gi|1022664304|ref|WP_063420886.1|	41.0	222	254	648	3.23e-44	156
k141_82821_2	SARG|gi|823309640|ref|WP_047064288.1|	41.0	222	254	648	3.23e-44	156
k141_82821_2	SARG|gi|505807117|ref|WP_015704872.1|	41.0	222	254	648	3.23e-44	156
k141_82821_2	SARG|gi|518923394|ref|WP_020079269.1|	41.0	222	254	648	3.23e-44	156
k141_82821_2	SARG|gi|695797094|ref|WP_032711285.1|	41.0	222	254	648	3.23e-44	156
k141_59403_3	SARG|NP_840140	55.1	276	310	273	2.17e-103	302
k141_59403_3	SARG|YP_294981	54.9	288	310	293	1.71e-102	301
k141_59403_3	SARG|YP_584847	53.7	294	310	293	2.26e-100	295
k141_59403_3	SARG|YP_746446	54.3	278	310	273	6.64e-100	293
k141_59403_3	SARG|Q4KC13	55.7	271	310	276	5.96e-99	291
k141_59403_3	SARG|YP_002006347	54.2	288	310	293	1.05e-98	291
k141_59403_3	SARG|Q880L3	56.1	271	310	276	3.41e-98	289
k141_59403_3	SARG|Q0K7S4	54.2	288	310	293	4.22e-98	290
k141_59403_3	SARG|CAY49038	53.2	278	310	276	4.83e-98	289
k141_59403_3	SARG|CAJ93947	54.2	288	310	306	6.47e-98	290
k141_59403_6	SARG|gi|1016521294|ref|WP_063100554.1|	37.1	229	348	648	2.84e-37	140
k141_59403_6	SARG|gb|AAV85982.1|ARO:3000535|macB	36.2	224	348	644	9.70e-37	139
k141_59403_6	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.4	211	348	307	7.01e-26	104
k141_59403_6	SARG|gb|AAK76137.1|ARO:3000024|patA	30.5	236	348	564	1.51e-23	100
k141_59403_6	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	24.0	196	348	524	2.39e-07	51.2
k141_83344_8	ResF|penA_1_AF515059_1	42.8	381	423	581	7.52e-88	277
k141_83344_8	SARG|gb|AQX82857.1|ARO:3004185|mecD	26.1	391	423	678	1.92e-17	83.6
k141_83344_8	SARG|gb|BAI83385.1|ARO:3003440|mecB	24.7	360	423	674	1.43e-16	80.9
k141_83344_8	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	24.2	360	423	674	1.06e-15	78.2
